Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLRK1 | P26718 | 7/20 | 0.53 |
| ▸ | MICA | Q29983 | 7/20 | 0.53 |
| ▸ | RAET1L | Q5VY80 | 5/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
| ▸ | RORB | Q92753 | 1/20 | 0.48 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | CTSA | P10619 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1308364 | 0.88 | ITGB1 (0.47) | KLRK1MICARAET1LMEN1MAPT | |
| SCHEMBL1307758 | 0.86 | KLRK1 (0.54) | KLRK1MICARAET1LKEAP1NFE2L2 | |
| SCHEMBL1309664 | 0.85 | KLRK1 (0.53) | KLRK1MICARAET1LRXFP1KEAP1 | |
| SCHEMBL22274977 | 0.77 | NPC1 (0.53) | RXFP1MEN1ALDH1A1LMNAMAPT | |
| SCHEMBL1307353 | 0.77 | KEAP1 (0.50) | KEAP1NFE2L2MEN1ALDH1A1LMNA | |
| SCHEMBL8752678 | 0.76 | NPSR1 (0.49) | KLRK1MICARAET1LMEN1ALDH1A1 | |
| SCHEMBL3455896 | 0.74 | RXFP1 (0.88) | RXFP1MEN1ALDH1A1LMNAMAPT | |
| SCHEMBL20764658 | 0.73 | CTSS (0.49) | KLRK1MICARAET1LRXFP1MEN1 | |
| SCHEMBL30117107 | 0.73 | CTSS (0.49) | KLRK1MICARAET1LRXFP1MEN1 | |
| SCHEMBL381877 | 0.73 | CTSS (0.49) | KLRK1MICARAET1LRXFP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | claimed |
| EP-1940792-A2 | AMINOPYRIMIDINE, AMINOPYRIDINE AND ANILINE DERIVATIVES INHIBITORS OF PIM-1 AND/OR PIM-3 | Exelixis, Inc. (US) | 2008-07-09 | — | — | EP | claimed |
| WO-2007044724-A2 | AMINOPYRIMIDINE, AMINOPYRIDINE AND ANILINE DERIVATIVES INHIBITORS OF PIM-I AND/OR PIM-3 | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | claimed |
| WO-2004022525-A1 | AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | claimed |
| US-8053454-B2 | Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| EP-1940792-A2 | AMINOPYRIMIDINE, AMINOPYRIDINE AND ANILINE DERIVATIVES INHIBITORS OF PIM-1 AND/OR PIM-3 | Exelixis, Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007044724-A2 | AMINOPYRIMIDINE, AMINOPYRIDINE AND ANILINE DERIVATIVES INHIBITORS OF PIM-I AND/OR PIM-3 | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2004022525-A1 | AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | PIM1, PIM3, PIM2 | KLRK1 2741/4885MICA 2838/4885RAET1L 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.